
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Indus is a leading generic drug manufacturer with a strong presence in North America, Europe, Japan, Russia, and Israel. It also has a portfolio of innovative medicines and biosimilars in the neurology and immunology therapeutic areas. The company is executing well against its Pivot to Growth plan, with a potential line of sight to 30% operating margin by 2027. The stock has high visibility into significant expansion in its neuroscience segment, and with continued advancement of its immunology-focused pipeline, we see further multiple expansion and growth opportunities.
Bears say
Teva Pharmaceutical Indus is expected to face stiff competition in the generic drug industry, as other companies enter the market and pricing pressures increase. The acquisition of Emalex adds to Teva's growing debt load, and there is uncertainty surrounding the success of its innovative medicines and biosimilars. Additionally, the slow uptake of Ecopipam and the potential for stronger uptake of Olanzapine LAI over Uzedy may also impact Teva's financial performance.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares